|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0001 - 0.0002|
|52 Week Range||0.0000 - 0.0016|
|Beta (5Y Monthly)||-6.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It has been a story of excitement for a vision, coupled with the hope of seeing come to life a revolutionary product that could one day help all of us Trust and Verify® what we put into our minds and bodies. This hope was partially realized with the creation of CannaDx™, a portable analyzer currently being used by thousands of consumers in the Cannabis industry to test the chemical profile of their cannabis and tracking how it makes them feel. From a business perspective, we expect the CannaDx product business unit, as a standalone division of the company, will continue to market, sell, and service this product, and believe it should be able to self-sustain itself and operate as a profitable business in the coming years.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, today issued a press release with the following letter to shareholders. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements.